Organic compounds

NATURELO Vitamin Supplements Now Available at Walgreens

Retrieved on: 
Friday, August 7, 2020

SEATTLE, Aug. 7, 2020 /PRNewswire/ --NATURELO supplements are now available at select Walgreens stores nationwide.

Key Points: 
  • SEATTLE, Aug. 7, 2020 /PRNewswire/ --NATURELO supplements are now available at select Walgreens stores nationwide.
  • For the first time, retail shoppers around the United States can find NATURELO vitamin supplements on the shelves of their local Walgreens store.
  • The NATURELO Wellness Series now available at Walgreens includes Whole Food Multivitamins for Men and Women made with real, organic fruits and vegetables, Prenatal vitamins, and plant-based Vitamin D3 and Vitamin C supplements for immune support.
  • Shoppers can use the NATURELO store locator to find the nearest Walgreens store that carries NATURELO Wellness Series products.

Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

Retrieved on: 
Friday, August 7, 2020

Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gileads investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gileads investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19.
  • Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizers McPherson, Kansas facility to manufacture and supply remdesivir for Gilead.
  • Pfizers agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions, said Albert Bourla, Chairman and Chief Executive Officer.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

1,3-Propanediol Market worth 691 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, August 7, 2020

Also, the growing demand for PTT in apparel and carpets is estimated to boost the growth of the 1,3-propanediol industry.

Key Points: 
  • Also, the growing demand for PTT in apparel and carpets is estimated to boost the growth of the 1,3-propanediol industry.
  • Polytrimethylene terephthalate (PTT) is estimated to be the largest application of 1,3-propanediol during the forecast period.
  • The Americas is the largest 1,3-propanediol market and is expected to continue its dominance during the forecast period.
  • Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM".

1,3-Propanediol Market worth 691 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, August 7, 2020

Also, the growing demand for PTT in apparel and carpets is estimated to boost the growth of the 1,3-propanediol industry.

Key Points: 
  • Also, the growing demand for PTT in apparel and carpets is estimated to boost the growth of the 1,3-propanediol industry.
  • Polytrimethylene terephthalate (PTT) is estimated to be the largest application of 1,3-propanediol during the forecast period.
  • The Americas is the largest 1,3-propanediol market and is expected to continue its dominance during the forecast period.
  • Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM".

DGAP-News: PAION ANNOUNCES SUCCESSFUL PRODUCT LAUNCH OF ANEREM (REMIMAZOLAM) IN JAPAN BY MUNDIPHARMA

Retrieved on: 
Friday, August 7, 2020

Aachen (Germany), 07 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that Mundipharma, remimazolam licensee for Japan, informed PAION about the successful launch with first commercial product sales of Anerem(R) (remimazolam) for the use in general anesthesia in Japan.

Key Points: 
  • Aachen (Germany), 07 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that Mundipharma, remimazolam licensee for Japan, informed PAION about the successful launch with first commercial product sales of Anerem(R) (remimazolam) for the use in general anesthesia in Japan.
  • PAION is eligible to royalties between 16-18% in Japan.
  • In Japan, licensee Mundipharma received market approval in general anesthesia in January 2020.
  • The topline data of a Phase III trial in general anesthesia are expected in the second half of 2020.

Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in China

Retrieved on: 
Friday, August 7, 2020

David Veitch, Chief Executive Officer, said: China is commercially a very important market for Cresemba, accounting for more than 15 percent of the global market for newer antifungals.

Key Points: 
  • David Veitch, Chief Executive Officer, said: China is commercially a very important market for Cresemba, accounting for more than 15 percent of the global market for newer antifungals.
  • We are therefore very pleased with the progress Pfizer is making in China, in order to address the unmet medical needs of patients suffering from invasive mold infections.
  • Under the agreement with Pfizer, Basilea is still eligible for regulatory and sales milestone payments of up to approximately USD630million, in addition to receiving mid-teen royalties on sales.
  • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 6, 2020

DUBLIN, Aug. 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ending June 30, 2020.

Key Points: 
  • DUBLIN, Aug. 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ending June 30, 2020.
  • We continue to forecast YUPELRI becoming a cash-flow positive brand in the United States (US) by the end of 2020."
  • Other risks affecting Theravance Biopharma are in the company's Form 10-Q filed with the SEC on May 8, 2020 and other periodic reports filed with the SEC.
  • In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results.

Genentech Provides Update on Phase III Study of Tecentriq in Combination With Paclitaxel for People With Metastatic Triple-Negative Breast Cancer

Retrieved on: 
Thursday, August 6, 2020

The insights will also be used to inform existing and future studies in TNBC with Tecentriq in combination with paclitaxel.

Key Points: 
  • The insights will also be used to inform existing and future studies in TNBC with Tecentriq in combination with paclitaxel.
  • Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers.
  • The IMpassion131 study is a Phase III, multi-center, randomized, double-blind study evaluating the efficacy and safety of Tecentriq in combination with paclitaxel, in comparison to placebo plus paclitaxel, in people with previously untreated, inoperable, locally advanced or metastatic TNBC.
  • The study enrolled 651 people who were randomized in a 2:1 ratio to receive Tecentriq or placebo plus paclitaxel.

Novateur Ventures explores new strategy to reduce the hyperinflammatory response caused by COVID-19

Retrieved on: 
Thursday, August 6, 2020

VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- A novel strategy has been developed by Novateur Ventures , which provides new hope in battle against COVID-19.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- A novel strategy has been developed by Novateur Ventures , which provides new hope in battle against COVID-19.
  • The study titled A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes was published in Frontiers in Pharmacology , a leading peer-reviewed journal.
  • The strategy co-authored by Ali Ardakani, Founder & Managing Director at Novateur Ventures, and Dr. Colin D. Funk (Queen's University, Kingston) analyzes lipid mediators, known as leukotrienes, as the cause for hyperinflammatory response manifested in severe COVID-19 cases.
  • The proposed zileuton/montelukast combination could readily be added in this setting, with the goal to switch off the hyper-inflammatory response.

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, August 6, 2020

This clinical trial collaboration supports our goal to optimize development of patritumab deruxtecan in patients with EGFR-mutated metastatic NSCLC to further improve current standards of care.

Key Points: 
  • This clinical trial collaboration supports our goal to optimize development of patritumab deruxtecan in patients with EGFR-mutated metastatic NSCLC to further improve current standards of care.
  • Daiichi Sankyo is pleased to begin this focused collaboration with AstraZeneca on this important aspect of patritumab deruxtecan development.
  • Patients enrolled in the first-line cohort will receive patritumab deruxtecan and TAGRISSO combination treatment, and patients in the second-line cohort will be randomized 1:1 to receive treatment with patritumab deruxtecan alone or in combination with TAGRISSO.
  • Patritumab deruxtecan (U3-1402) is one of three lead DXd antibody drug conjugates (ADC) in the oncology pipeline of Daiichi Sankyo.